Displaying 1 - 20 of 40
| Active Ingredient | ANTIDIABETIC AGENTS |
| Therapeutic Class | ANTIDIABETIC AGENTS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ACARBOSE |
| Therapeutic Class | ALPHA GLUCOSIDASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | METFORMIN |
| Therapeutic Class | BIGUANIDES |
| Indications |
Diabetes mellitus in obese, mature onset, diabetes without ketosis, when diet and attempts at weight loss fail. |
| Caution |
Anorexia or dyspep sia occurs in 15% of cases. Lactic acidosis is an infrequent side effect. Nausea, vomiting, diarrhoea, flatulence. C.f. Prescribing in liver and renal disease p. 15; 32. Not recom More ... |
| Dose Range |
500mg 2-3 times daily or 850mg once or twice daily with or after meals. Gradually increase at intervals of at least 1 week, to 2- 3 g daily . Doses greater than 2g, give in 3 divided doses. Extended Release: Initial dose of 500 mg once daily in |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | METFORMIN XR |
| Therapeutic Class | BIGUANIDES |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | LINAGLIPTIN |
| Therapeutic Class | DIPEPTIDYL PEPTIDASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | METFORMIN XR | SITAGLIPTIN |
| Therapeutic Class | DIPEPTIDYL PEPTIDASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | METFORMIN | SAXAGLIPTIN |
| Therapeutic Class | DIPEPTIDYL PEPTIDASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | METFORMIN | SITAGLIPTIN |
| Therapeutic Class | DIPEPTIDYL PEPTIDASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | METFORMIN | VILDAGLIPTIN |
| Therapeutic Class | DIPEPTIDYL PEPTIDASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | SITAGLIPTIN |
| Therapeutic Class | DIPEPTIDYL PEPTIDASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | SITAGLIPTIN | METFORMIN |
| Therapeutic Class | DIPEPTIDYL PEPTIDASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | VILDAGLIPTIN |
| Therapeutic Class | DIPEPTIDYL PEPTIDASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | VILDAGLIPTIN | METFORMIN |
| Therapeutic Class | DIPEPTIDYL PEPTIDASE INHIBITORS |
| Indications | Type 2 diabetes mellitus as monotherapy (if metformin inappropriate), or in combination with other antidiabetic drugs (including insulin) if existing treatment fails to achieve adequate glycaemic cont More ... |
| Caution | Asthenia, dizziness, headache, nausea;, peripheral oedema, tremor. |
| Dose Range | 1 tablet twice daily based on patient’s current metformin dose. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ASPART |
| Therapeutic Class | INSULINS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | DETEMIR |
| Therapeutic Class | INSULINS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | GLARGINE |
| Therapeutic Class | INSULINS |
| Indications | Diabetes mellitus. For use in patients with Type I Diabetes. |
| Caution |
Local reactions, fat hypertrophy at injection site. Insulin glargine preparations are not bioequivalent ; dose adjustment and close metabolic monitoring is recommended if switching bet More ... |
| Dose Range | Once daily at the same time each day. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | GLULISINE |
| Therapeutic Class | INSULINS |
| Indications | Diabetes mellitus. For use in patients with Type I Diabetes. |
| Caution | Local reactions, fat hypertrophy at injection site. |
| Dose Range | Immediately before meals or when necessary shortly sfter meals, according to requirements. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | INSULIN ISOPHANE |
| Therapeutic Class | INSULINS |
| Indications | Diabetes Mellitus. |
| Caution | See under Insulin (lente), Zinc Suspension, Human. |
| Dose Range | See under Insulin (lente), Zinc Susp ension, Human. See BDS supply protocols pg. 7. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | INSULIN ISOPHANE | INSULIN RAPID |
| Therapeutic Class | INSULINS |
| Indications | Diabetes Mellitus. |
| Caution | Hypoglycemia. |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | INSULIN RAPID |
| Therapeutic Class | INSULINS |
| Indications | Diabetes Mellitus |
| Caution | See under Insulin (lente), Zinc Suspension, Human. |
| Dose Range |
See under Insulin (lente), Zinc Suspension, Human. See BDS supply protocols pg. 7. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |